glp 1 in non diabetic GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity | Saudi Pharmaceutical Journal Insights from Specialty Physicians on

Additionally, these agents suppress glucagon secretion, slow gastric emptying, and act on central appetite centers in the brain to increase satiety and reduce food intake

Not intended to diagnose, treat, cure, or prevent any disease or condition

This has been called out as a contributing factor to patient anxiety

People might also feel short of breath and dizzy , mainly when theyre active

1 Introduction Besides the traditional standard-of-care agents, newer classes of glucose-lowering agents have been introduced and changed the landscape of type 2 diabetes mellitus (T2DM) management ( The CV benefits were variable among the different available GLP-1 RAs

PMCID: PMC9807016